Update: geovax announces phase 2 plans for gedeptin® cancer therapy following clinical advisory committee review

Company plans phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor
GOVX Ratings Summary
GOVX Quant Ranking